Janux Therapeutics (JANX) Assets Average (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Assets Average fell 3.91% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 3.91% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 43.08% from the prior year.
• Assets Average for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• Over the last five years, Assets Average for JANX reached as high as $1.1 billion in Q1 2025 and fell as low as $347.2 million in Q2 2023.
• Historically, Assets Average has averaged $641.5 million across 5 years, with a median of $534.7 million in 2024.
• Across the five-year window, Assets Average decreased 7.89% in 2023 and jumped 128.94% in 2024, its largest moves.
• Year by year, Assets Average stood at $369.9 million in 2022, then gained by 3.72% to $383.6 million in 2023, then soared by 128.94% to $878.3 million in 2024, then climbed by 15.36% to $1.0 billion in 2025, then climbed by 0.17% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.